Search

Your search keyword '"Meune C"' showing total 348 results
Start Over Author "Meune C"
348 results on '"Meune C"'

2. Effects of cannabis on pulmonary arterial pressure in patients hospitalized for acute cardiac events: From the ADDICT-ICCU study

Author

Gonçalves, T., primary, Pezel, T., additional, Fauvel, C., additional, Bauer, F., additional, Ouahidi, A. El, additional, Zakine, C., additional, Bouleti, C., additional, Mansencal, N., additional, Dib, J.C., additional, Goralski, M., additional, Thuaire, C., additional, Bochaton, T., additional, Pommier, T., additional, Lemarchand, L., additional, Meune, C., additional, Delmas, C., additional, Dillinger, J.-G., additional, and Henry, P., additional

Published
2024
Full Text
View/download PDF

3. In-hospital prognostic value of TAPSE/sPAP in patients hospitalized for acute heart failure

Author

Fauvel, C., primary, Pezel, T., additional, Rossanaly Vasram, R., additional, Charbonnel, C., additional, Bouleti, C., additional, Logeart, D., additional, Roubille, F., additional, Meune, C., additional, Nhan, P., additional, Ohlmann, P., additional, Bonnefoy-Cudraz, E., additional, Albert, F., additional, Andrieu, S., additional, Dillinger, J.-G., additional, and Henry, P., additional

Published
2024
Full Text
View/download PDF

4. Machine-learning score to predict in-hospital outcomes in patients Hospitalized in Intensive Cardiac Care Unit

Author

Weizman, O, primary, Pezel, T, additional, Hamzi, K, additional, Schurtz, G, additional, Hauguel-Moreau, M, additional, Trimaille, A, additional, Toupin, S, additional, Bochaton, T, additional, Attou, S, additional, Meune, C, additional, Boccara, F, additional, Pasdeloup, B, additional, El Ouahidi, Y, additional, Dillinger, J G, additional, and Henry, P, additional

Published
2023
Full Text
View/download PDF

5. In-hospital Prognostic Value of TAPSE/sPAP in Patients Hospitalized for Acute Heart Failure

Author

Fauvel, C, primary, Pezel, T, additional, Rossanaly Vasram, R, additional, Charbonnel, C, additional, Bouleti, C, additional, Logeart, D, additional, Roubille, F, additional, Meune, C, additional, Nhan, P, additional, Ohlmann, P, additional, Bonnefoy-Cudraz, E, additional, Albert, F, additional, Andrieu, S, additional, Dillinger, J G, additional, and Henry, P, additional

Published
2023
Full Text
View/download PDF

8. Expiratory carbon monoxide level is a key determinant of prognosis in smokers with acute cardiac events

Author

Dillinger, J.-G., primary, Pezel, T., additional, Delmas, C., additional, Schurtz, G., additional, Trimaille, A., additional, Bouleti, C., additional, Albert, F., additional, Dib, J.C., additional, Mérat, B., additional, Boccara, A., additional, Andrieu, S., additional, Bouali, N., additional, Fabre, J., additional, Meune, C., additional, Pamart, S., additional, Gall, E., additional, Boccara, F., additional, Aboyans, V., additional, Puymirat, E., additional, and Henry, P., additional

Published
2023
Full Text
View/download PDF

27. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis

Author

Allanore, Y, Meune, C, Vonk, M C, Airo, P, Hachulla, E, Caramaschi, P, Riemekasten, G, Cozzi, F, Beretta, L, Derk, C T, Komócsi, A, Farge, D, Balbir, A, Riccieri, V, Distler, O, Chialà, A, Papa, Del N, Simic, Pasalic K, Ghio, M, Stamenkovic, B, Rednic, S, Host, N, Pellerito, R, Zegers, E, Kahan, A, Walker, U A, and Matucci-Cerinic, M

Published
2010
Full Text
View/download PDF

36. Mapping and predicting mortality from systemic sclerosis

Author

Elhai, M. Meune, C. Boubaya, M. Avouac, J. Hachulla, E. Balbir-Gurman, A. Riemekasten, G. Airò, P. Joven, B. Vettori, S. Cozzi, F. Ullman, S. Czirják, L. Tikly, M. Müller-Ladner, U. Caramaschi, P. Distler, O. Iannone, F. Ananieva, L.P. Hesselstrand, R. Becvar, R. Gabrielli, A. Damjanov, N. Salvador, M.J. Riccieri, V. Mihai, C. Szücs, G. Walker, U.A. Hunzelmann, N. Martinovic, D. Smith, V. Müller, C.D.S. Montecucco, C.M. Opris, D. Ingegnoli, F. Vlachoyiannopoulos, P.G. Stamenkovic, B. Rosato, E. Heitmann, S. Distler, J.H.W. Zenone, T. Seidel, M. Vacca, A. Langhe, E.D. Novak, S. Cutolo, M. Mouthon, L. Henes, J. Chizzolini, C. Mühlen, C.A.V. Solanki, K. Rednic, S. Stamp, L. Anic, B. Santamaria, V.O. Santis, M.D. Yavuz, S. Sifuentes-Giraldo, W.A. Chatelus, E. Stork, J. Laar, J.V. Loyo, E. De La Peña Lefebvre, P.G. Eyerich, K. Cosentino, V. Alegre-Sancho, J.J. Kowal-Bielecka, O. Rey, G. Matucci-Cerinic, M. Allanore, Y.

Abstract

Objectives To determine the causes of death and risk factors in systemic sclerosis (SSc). Methods Between 2000 and 2011, we examined the death certificates of all French patients with SSc to determine causes of death. Then we examined causes of death and developed a score associated with all-cause mortality from the international European Scleroderma Trials and Research (EUSTAR) database. Candidate prognostic factors were tested by Cox proportional hazards regression model by single variable analysis, followed by a multiple variable model stratified by centres. The bootstrapping technique was used for internal validation. Results We identified 2719 French certificates of deaths related to SSc, mainly from cardiac (31%) and respiratory (18%) causes, and an increase in SSc-specific mortality over time. Over a median follow-up of 2.3 years, 1072 (9.6%) of 11 193 patients from the EUSTAR sample died, from cardiac disease in 27% and respiratory causes in 17%. By multiple variable analysis, a risk score was developed, which accurately predicted the 3-year mortality, with an area under the curve of 0.82. The 3-year survival of patients in the upper quartile was 53%, in contrast with 98% in the first quartile. Conclusion Combining two complementary and detailed databases enabled the collection of an unprecedented 3700 deaths, revealing the major contribution of the cardiopulmonary system to SSc mortality. We also developed a robust score to risk-stratify these patients and estimate their 3-year survival. With the emergence of new therapies, these important observations should help caregivers plan and refine the monitoring and management to prolong these patients' survival. ©Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2017. All rights reserved. No commercial use is permitted unless otherwise expressly granted.

Published
2017

43. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of systemic sclerosis patients

Author

Allanore, Y, Meune, C, Vonk, Mc, Airo, P, Hachulla, E, Caramaschi, P, Riemekasten, G, Cozzi, Franco, Beretta, L, Derk, Ct, KOMÃ'SI, A, Farge, D, Balbir, A, Riccieri, V, Distler, O, CHIALÀ, A, DEL PAPA, N, SIMIC PASALIC, K, Ghio, M, Stamenkovic, B, Rednic, S, Host, N, Pellerito, R, Zegers, E, Kahan, A, Walker, Ua, and MATUCCI CERINIC, M.

Subjects
left ventricular dysfunction, calcium channel blockers, Systemic sclerosis
Published
2010

44. Diagnostic accuracy of combined cardiac troponin and copeptin assessment for early rule-out of myocardial infarction: : a systematic review and meta-analysis

Author

Raskovalova, T, Twerenbold, R, Collinson, PO, Keller, T, Bouvaist, H, Folli, C, Giavarina, D, Lotze, U, Eggers, Kai, Dupuy, AM, Chenevier-Gobeaux, C, Meune, C, Maisel, A, Mueller, C, Labarère, J, Raskovalova, T, Twerenbold, R, Collinson, PO, Keller, T, Bouvaist, H, Folli, C, Giavarina, D, Lotze, U, Eggers, Kai, Dupuy, AM, Chenevier-Gobeaux, C, Meune, C, Maisel, A, Mueller, C, and Labarère, J

Abstract

AIMS: This systematic review aimed to investigate the diagnostic accuracy of combined cardiac troponin (cTn) and copeptin assessment in comparison to cTn alone for early rule-out of acute myocardial infarction (AMI). METHODS: Primary studies were eligible if they evaluated diagnostic accuracy for cTn with and without copeptin in patients with symptoms suggestive of AMI. AMI was defined according to the universal definition, using detection of cTn as a marker for myocardial necrosis. Eligible studies were identified by searching electronic databases (Medline, EMBASE, Science Citation Index Expanded, CINAHL, Pascal, and Cochrane) from inception to March 2013, reviewing conference proceedings and contacting field experts and the copeptin manufacturer. RESULTS: In 15 studies totalling 8740 patients (prevalence of AMI 16%), adding copeptin improved the sensitivity of cTn assays (from 0.87 to 0.96, p=0.003) at the expense of lower specificity (from 0.84 to 0.56, p<0.001). In 12 studies providing data for 6988 patients without ST-segment elevation, the summary sensitivity and specificity estimates were 0.95 (95% CI 0.89 to 0.98) and 0.57 (95% CI 0.49 to 0.65) for the combined assessment of cTn and copeptin. When a high-sensitivity cTnT assay was used in combination with copeptin, the summary sensitivity and specificity estimates were 0.98 (95% CI 0.96 to 1.00) and 0.50 (95% CI 0.42 to 0.58). CONCLUSION: Despite substantial between-study heterogeneity, this meta-analysis demonstrates that copeptin significantly improves baseline cTn sensitivity. Management studies are needed to establish the effectiveness and safety of measuring copeptin in combination with high-sensitivity cTnT for early rule-out of AMI without serial testing.

Published
2014
Full Text
View/download PDF

48. Prevalence and factors associated with left ventricular dysfunction in the EULAR Scleroderma Trial and Research group (EUSTAR) database of patients with systemic sclerosis.

Author

Allanore, Y., Meune, C., Vonk, M.C., Airo, P., Hachulla, E., Caramaschi, P., Riemekasten, G., Cozzi, F., Beretta, L., Derk, C.T., Komocsi, A., Farge, D., Balbir, A., Riccieri, V., Distler, O., Chiala, A., Papa, N.D., Simic, K.P., Ghio, M., Stamenkovic, B., Rednic, S., Host, N., Pellerito, R., Zegers, E., Kahan, A., Walker, U.A., Matucci-Cerinic, M., Allanore, Y., Meune, C., Vonk, M.C., Airo, P., Hachulla, E., Caramaschi, P., Riemekasten, G., Cozzi, F., Beretta, L., Derk, C.T., Komocsi, A., Farge, D., Balbir, A., Riccieri, V., Distler, O., Chiala, A., Papa, N.D., Simic, K.P., Ghio, M., Stamenkovic, B., Rednic, S., Host, N., Pellerito, R., Zegers, E., Kahan, A., Walker, U.A., and Matucci-Cerinic, M.

Abstract

1 januari 2010, Item does not contain fulltext, OBJECTIVES: To measure the prevalence of, and factors associated with, left ventricular (LV) dysfunction in systemic sclerosis (SSc). METHODS: The EUSTAR database was first searched. A case-control study of a patient subset was then performed to further identify independent factors associated with LV dysfunction by simple and multiple regression. RESULTS: Of 7073 patients, 383 (5.4%) had an LV ejection fraction (EF) of <55%. By multiple regression analysis, age, sex, diffuse cutaneous disease, disease duration, digital ulcerations, renal and muscle involvement, disease activity score, pulmonary fibrosis and pulmonary arterial hypertension were associated with LV dysfunction. In the second phase, 129 patients with SSc with LVEF <55% were compared with 256 patients with SSc with normal LVEF. Male sex (OR 3.48; 95% CI 1.74 to 6.98), age (OR 1.03; 95% CI 1.01 to 1.06), digital ulcerations (OR 1.91; 95% CI 1.05 to 3.50), myositis (OR 2.88; 95% CI 1.15 to 7.19) and use of calcium channel blockers (OR 0.41; 95% CI 0.22 to 0.74) were independent factors associated with LV dysfunction. CONCLUSION: The prevalence of LV dysfunction in SSc is 5.4%. Age, male gender, digital ulcerations, myositis and lung involvement are independently associated with an increased prevalence of LV dysfunction. Conversely, the use of calcium channel blockers may be protective.

Published
2010

Catalog

Books, media, physical & digital resources
See catalog results